
Target price is 2.78/261.80%. 1.99/161.80% is a critical support level.
Heat Biologics, Inc.
627 Davis Drive
Suite 400
Morrisville, NC 27560
United States
919 240 7133
http://www.heatbio.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 36
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion. The company’s T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company’s preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Target price is 2.78/261.80%. 1.99/161.80% is a critical support level.
0.729/261.80% and 0.786 Fibo untrend fan line work for support.